Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VKTX Stock Price Chart Interactive Chart >
VKTX Price/Volume Stats
| Current price | $6.28 | 52-week high | $10.09 |
| Prev. close | $6.40 | 52-week low | $4.95 |
| Day low | $6.09 | Volume | 951,816 |
| Day high | $6.42 | Avg. volume | 1,214,465 |
| 50-day MA | $5.87 | Dividend yield | N/A |
| 200-day MA | $6.32 | Market Cap | 490.47M |
Viking Therapeutics, Inc. (VKTX) Company Bio
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Latest VKTX News From Around the Web
Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
Why Viking Therapeutics Stock Briefly Popped TodayWhat happened Shares of the developmental-stage biotech Viking Therapeutics (NASDAQ: VKTX) jumped by as much as 11.2% in pre-market action Thursday morning. The company's shares perked up in response to an intriguing top-line readout for the experimental X-linked adrenoleukodystrophy (X-ALD) drug dubbed VK0214 in a phase 1 trial. |
Viking Therapeutics' VK0214 Shows Encouraging Safety, Tolerability Profile In Healthy VolunteersViking Therapeutics Inc (NASDAQ: VKTX) has announced results from its Phase 1 trial of VK0214 in healthy volunteers. VK0214 demonstrated encouraging safety and tolerability at all doses, as well as a predictable pharmacokinetic (PK) profile. No serious adverse events were reported, and no treatment or dose-related trends were observed for vital signs, gastrointestinal effects, cardiovascular measures, or physical examinations. VK0214 demonstrated dose-dependent exposures, no evidence of accumula |
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK0214, a novel, orally available small molecule thyroid receptor beta (TRβ) agonist in development for the potential treatment for X-linked adrenoleukodystrophy (X-ALD). In this study, VK02 |
Viking Therapeutics to Participate in Upcoming Investor ConferencesViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences. |
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOsHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB ) Nuvation Bio Inc. (NYSE: NUVB ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) PLx Pharma Inc. (NASDAQ: PLXP ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 26) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Axcella Health Inc. (NASDAQ: AXLA ) Black Diamond Therapeutics, Inc. (NASDAQ: BDTX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Coherus BioSciences, Inc. (NASDAQ: CHRS ) Evofem Biosciences, Inc. (NASDAQ: EVFM ) Impel NeuroPharma, Inc. (NASDAQ: IMPL ) IMV Inc. (NASDAQ: IMV ) Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT... |
VKTX Price Returns
| 1-mo | 6.26% |
| 3-mo | -0.16% |
| 6-mo | -2.18% |
| 1-year | -16.49% |
| 3-year | -48.61% |
| 5-year | 372.18% |
| YTD | 11.55% |
| 2020 | -29.80% |
| 2019 | 4.84% |
| 2018 | 88.42% |
| 2017 | 241.18% |
| 2016 | -65.10% |
Loading social stream, please wait...